Efgartigimod Shows Promise in Treating Immune Checkpoint Inhibitor-Associated Myocarditis and Myasthenia Gravis
Key Insights
A 69-year-old bladder cancer (search) patient developed severe myasthenia gravis (search) crisis and asymptomatic myocarditis (search) 16 days after receiving tislelizumab, requiring immediate intervention with efgartigimod and corticosteroids.
Efgartigimod, an FcRn (search) antagonist that accelerates pathogenic antibody degradation, demonstrated rapid therapeutic effects when combined with prednisone, leading to significant improvement in muscle strength scores and cardiac biomarkers.
This case represents the first reported use of efgartigimod for treating the complex overlap syndrome of ICI-associated myocarditis (search) and myasthenia gravis (search), offering a new therapeutic approach for these life-threatening immune-related adverse events.
A novel therapeutic approach using efgartigimod has shown promising results in treating the rare but potentially fatal combination of immune checkpoint inhibitor-associated myocarditis (search) and myasthenia gravis (search), according to a case report published in Frontiers in Immunology.
The case involves a 69-year-old female bladder cancer (search) patient who developed severe complications 16 days after receiving tislelizumab, a PD-1 (search) inhibitor. The patient presented with impending myasthenic crisis characterized by complete left eyelid ptosis, neck weakness, dysarthria, and respiratory distress, alongside asymptomatic myocarditis (search) evidenced by elevated cardiac biomarkers.
Rapid Clinical Deterioration
Laboratory findings revealed significantly elevated cardiac injury markers, including creatine kinase (443 U/L), troponin I (0.051 ng/mL), and troponin T (0.355 ng/mL). The patient's myasthenia gravis (search) severity was quantified using standardized scoring systems, with MG-ADL and QMG scores of 11 and 26 respectively at admission, indicating severe functional impairment.
Anti-acetylcholine receptor (search) antibodies were markedly elevated at 4.687 nmol/L, confirming the autoimmune nature of the condition. Cardiac magnetic resonance imaging revealed mild myocardial edema without significant late gadolinium enhancement, supporting the diagnosis of non-fulminant myocarditis (search).
Novel Treatment Strategy
Given the patient's critical condition and the family's refusal of high-dose steroid pulse therapy, clinicians implemented an innovative treatment approach combining efgartigimod with oral corticosteroids. Efgartigimod, an FcRn (search) antagonist that accelerates the degradation of pathogenic IgG antibodies, was administered intravenously at 10 mg/kg weekly for four cycles.
The treatment regimen followed the ADAPT clinical trial protocol, with efgartigimod (600 mg) given alongside oral prednisone acetate (60 mg daily). This combination was chosen to provide rapid antibody clearance while avoiding the complications associated with high-dose steroid therapy.
Remarkable Clinical Response
The patient demonstrated significant improvement within 24 hours of treatment initiation. Dyspnea and neck muscle strength improved markedly, with progressive normalization of cardiac biomarkers and liver function tests over the following weeks.
Functional assessments showed dramatic improvement, with MG-ADL scores decreasing from 11 to 4 and QMG scores dropping from 26 to 8 by week three. Cardiac injury markers, which peaked around February 14, rapidly declined and returned to normal levels by late February, indicating effective resolution of myocardial involvement.
Serum IgG levels demonstrated the expected pharmacodynamic profile, declining from 11.6 g/L at week one to 3.5 g/L by week six, followed by stabilization at 6.2 g/L at week eight.
Clinical Significance
This case represents the first reported use of efgartigimod for treating ICI-associated myocarditis (search) with concurrent myasthenia gravis (search). The overlap syndrome, often referred to as the "terrible triad" when including myositis, carries a mortality rate exceeding 50% according to previous literature.
The pathological mechanism involves cross-reactive antigen responses and T-cell dysregulation, where PD-1 (search) pathway blockade leads to T-cell recognition of shared antigens in skeletal and cardiac muscle. Efgartigimod's mechanism of selectively blocking IgG recycling offers advantages over traditional therapies like plasma exchange or intravenous immunoglobulin.
Treatment Advantages
Compared to conventional salvage therapies, efgartigimod offers several clinical advantages. The treatment provides convenient intravenous administration with rapid onset of action and lower immunosuppression risk. This is particularly relevant for patients with contraindications to other therapies, such as the venous thrombosis present in this case.
The multidisciplinary team approach proved crucial in managing this complex case, involving oncology, cardiology, nephrology, neurology, and geriatrics specialists. The collaborative decision-making process enabled optimal treatment selection while respecting patient and family preferences.
Broader Implications
With the expanding use of immune checkpoint inhibitors across various malignancies, clinicians must maintain heightened awareness for rare but severe immune-related adverse events. The incidence of ICI-associated myocarditis (search) ranges from 0.1% to 1%, but mortality rates can reach 25% to 50% in symptomatic patients.
The successful use of efgartigimod in this case suggests potential applications beyond its current indication for myasthenia gravis (search). The drug's mechanism of accelerating pathogenic antibody degradation may prove beneficial in other antibody-mediated immune toxicities associated with cancer immunotherapy.
This case underscores the importance of early recognition, prompt intervention, and innovative therapeutic approaches in managing complex immune-related adverse events. The favorable outcome achieved with efgartigimod and moderate-dose corticosteroids provides a valuable treatment option for similar cases, potentially improving outcomes while minimizing treatment-related complications.